You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A nanoparticle-based vaccine against leishmaniasis

    SBC: L2 DIAGNOSTICS LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): We propose to develop a recombinant subunit vaccine against cutaneous leishmaniasis. This vaccine will incorporate two protein antigens, TSA/TryP and P-4. Both antigens are highly conserved among Leishmania species, arerecognized by T cells of human patients, and confer protection against a live challenge in murine model studies. We expect that immunization usi ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  2. T cell cytokine assay for the diagnosis of disseminated Lyme borreliosis

    SBC: L2 DIAGNOSTICS LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): Lyme disease, due to infection with the Ixodes tick-transmitted spirochete Borrelia burgdorferi, is the most common vector-borne disease in the United States, with more than 28,000 cases reported annually. The infectioncan remain localized to the skin or disseminate to cause disease in the skin, heart, joints and nervous system. The ospC genotype of the spiroch ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  3. A vaccine against Clostridium difficile infections

    SBC: SORRENTO THERAPEUTICS, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): In this proposal we lay out a comprehensive research plan to evaluate our vaccination strategies targeting Clostridium difficile to prevent or treat infections. With the emergence of highly antibiotic-resistant bacterial strains, new approaches for combating bacterial infections are desperately needed. In this research proposal, Sorrento Therapeutics Inc. (STI ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  4. Feasibility of a New Thermo-brachytherapy Seed for Concurrent Brachytherapy and H

    SBC: Best Medical International, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): Adjuvant administration of radiation therapy with hyperthermia in treatment of cancer has been studied extensively in the past three decades (Deger et al., 2004), but simultaneous delivery of these modalities using thesame source has not been documented. Here we propose feasibility study, development and clinical implementation of a new Thermo-brachytherapy see ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  5. Backbone Degradable Polymer-drug Conjugates for the Treatment of Ovarian Cancer

    SBC: THERATARGET, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): This Phase I proposal details the rationale and the research plan for the synthesis and characterization of targeted, backbone degradable, long-circulating polymer conjugates containing two anticancer drugs per macromolecule. The polymeric carrier will be composed of alternating N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer segments (blocks) and enzymatica ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  6. Liposomal Nicotine Vaccine Development

    SBC: MOLECULAR EXPRESS, INC            Topic: NIDA

    DESCRIPTION (provided by applicant): In response to RFA-DA-11-004, we propose in this STTR Phase I application to develop and test a nicotine vaccine utilizing a chemical derivative of the drug, or hapten, coupled to an immunostimulatory, adjuvant-containing liposome. The current approach to curbing nicotine addiction is the use of over the counter nicotine replacement products, but this approach ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  7. In vivo and in vitro tools to target CHRNA5 for smoking cessation.

    SBC: OPHIDION, INC.            Topic: NIDA

    DESCRIPTION (provided by applicant): Nicotine is one of the most heavily used addictive drugs and accounts for 90% of lung cancer cases in the U.S. Recent studies have implicated a specialized receptor class binding to nicotine, the CHRNA5 gene, which encodes the a5 subunit of the nicotinic receptor, as a contributing factor in the risk towards nicotine dependence. This, along with animal studies ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  8. CG-GRID: Computational Genetics Grid Resource for Interaction Discovery

    SBC: PARABON COMPUTATION, INC.            Topic: NIGMS

    DESCRIPTION (provided by applicant): Susceptibility to common human diseases such as cancer and cardiovascular disease is determined by numerous genetic factors that interact in a nonlinear manner in the context of an individual's age and environmental exposure. This complex genetic architecture has important implications for the use of genome- wide association studies (GWAS) for identifying ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  9. Injury-targeted decorin for systemic anti-fibrotic treatment

    SBC: VASCULAR BIOSCIENCES, INC.            Topic: NIGMS

    DESCRIPTION (provided by applicant): The repair of injuries is dominated by a tendency to re-establish tissue continuity rather than restoring the structure of the original tissue. This process results in scarring and fibrosis, which is a major medical problem spanning diseases in all organ systems. This application focuses on a compound that has been shown to be highly effective in reducing scarr ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  10. Development of novel adenosine polymers for coating medical devices

    SBC: NUVIEW LIFE SCIENCES, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Percutaneous coronary intervention (PCI) is the most frequently employed strategy to revascularize atherosclerotic stenosis of native coronary arteries and saphenous vein grafts. Tissue perfusion is frequently impairedfollowing PCI, particularly in patients with ST segment elevation myocardial infarction (STEMI). This results in the no-reflow phenomenon which ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government